17,261 trials
Rhabdomyosarcoma · Melanoma
Primary: Average Number of Lymph Nodes Identified Intraoperatively Per Subject — 3.30 nodes per subject
Ulcerative Colitis
Primary: Percentage of Participants in Cohort 1 Achieving Clinical Remission — 26.5; 1.5 Percentage of participants — p=<.0001
Bladder Cancer
Primary: Clinical Complete Response (CCR) Rate — 43 Percentage of participants
Plaque Psoriasis
Primary: Percentage of Participants Achieving Greater Than or Equal to (>=) 75% Reduction From Baseline in Psoriasis Area Severity Index (PASI) Score (PASI-75) at Week 16 — 58.3…
Tenosynovial Giant Cell Tumor · Pigmented Villonodular Synovitis (PVNS)
Primary: Number of Participants With Treatment-emergent Adverse Events — 7; 2 Participants
Neoplasms
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Daily Oral Lisavanbulin — 16; 30 mg
Posttraumatic Headache · Combat Disorders · Post Concussion Syndrome
Primary: Headache Diary — -10.7; -6.9 headaches per month — p=0.034
Bipolar Disorder · Bipolar I Disorder · Bipolar II Disorder
Primary: Change in dACC GSH Levels Through Proton Magnetic Resonance Spectroscopy — 2.426; 2.207 Institutional Units
Alopecia Areata
Primary: Percent Change From Baseline in Severity of Alopecia Tool I (SALT I) at Week 24: DB Treatment Period — -13.79; -21.43; 0.35 Percent change of scalp surface area — p=0.2579
Osteoarthritis
Primary: Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.13; -1.43 score on a scale
Relapsed or Refractory Peripheral T-Cell Lymphoma
Primary: Objective Response Rate (ORR) — 56.3; 7.1; 40.0; 0.0 percentage of participants — p=0.000
Recurrent Skin Carcinoma · Skin Squamous Cell Carcinoma
Primary: Response Rate of Pembrolizumab — 72.73 percentage of participants
Glioblastoma · Glioblastoma With Primitive Neuronal Component · Gliosarcoma
Primary: Proportion of Progression Free Survival Participants (PFS) at Six Months — 0.786 Proportion of participants
Mycoses · Candidiasis, Invasive · Candidemia
Primary: Safety and Tolerability, Assessed by Adverse Events, Clinical Laboratory Results, Physical Examination Findings, ECG Results, and Vital Sign Measurements — 1; 1; 0; 0…
Metastatic Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 1.5; 2.7 Months